The Role of the IGF Axis in Tumorigenesis and Cancer Treatment: From Genes to Metabolites

13.7K
views
52
authors
5
articles
Editors
4
Impact
Loading...

Background: Laryngeal cancer (LC) is a prevalent head and neck malignancy; however, the essential pathophysiological mechanism underlying its tumorigenesis and progression remains elusive. Due to the perduring scarcity of effective targeted drugs for laryngeal cancer, insights into the disease’s pathophysiological mechanisms would substantially impact the treatment landscape of laryngeal cancer.

Methods: To ensure quality consistency, 10 tumor and 9 non-tumor samples underwent proteomic analysis on a single mass spectrometer using a label-free technique. Subsequently, gene expression variations between laryngeal squamous cell carcinoma and normal tissues were analyzed using The Cancer Genome Atlas (TCGA) database. Immunohistochemical expressions of insulin-like growth factor 2 receptor (IGF2R), fibronectin (FN), vimentin, and α-smooth muscle actin (SMA) in LC tissues and normal tissues were determined.

Results: In the tumor group, significant variations were detected for 433 upregulated and 61 downregulated proteins. Moreover, the heatmap revealed that the expressions of RNA translation-related proteins and proteins involved in RNA metabolism, such as IGF2R, tenascin C (TNC), periostin (POSTN), proteasome 26S subunit ATPase 4 (PSMC4), serpin family A member 3 (SERPINA3), heat shock protein family B (small) member 6 (HSPB6), osteoglycin (OGN), chaperonin containing TCP1 subunit 6A (CCT6A), and chaperonin containing TCP1 subunit 6B (CCT6B), were prominently elevated in the tumor group. Nonsense-mediated RNA decay (NMD), RNA translation, and protein stability were significantly altered in LC tumors. IGF2R was remarkably upregulated in LC tumors. In the TCGA database, the IGF2R mRNA level was significantly upregulated in LSCC tissues. Additionally, IGF2R mRNA expression was lowest in clinical grade 1 samples, with no significant difference between grades 2 and 3. In LSCC patients, a significant positive correlation between IGF2R expression and the stromal score was detected using the ESTIMATE algorithm to estimate the immune score, stromal score, and tumor purity in the tumor microenvironment. Lastly, immunohistochemical analysis revealed that IGF2R is overexpressed in LC.

Conclusion: These results demonstrate the vital role of IGF2R in LC carcinogenesis and progression and may facilitate the identification of new therapeutic targets for the prevention and treatment of LC.

4,167 views
9 citations
Original Research
28 July 2022
Small molecules to regulate the GH/IGF1 axis by inhibiting the growth hormone receptor synthesis
Lieke M. van der Velden
12 more and 
Ger J. Strous
A. Compounds BM001, BM002 and BM003 inhibit tumor growth. Bioluminescence imaging was used to visualize tumor growth over time (A) and tumor volumes were longitudinally measured in response to the indicated BM compounds (B, C). BM001 treatment results in a dose-dependent reduction in plasma IGF1 levels (D) and liver weight (E). Statistical analysis was performed with GraphPad Prism 8.0 (San Diego, CA, USA). Data is presented as mean SEM.

Growth hormone (GH) and insulin‐like growth factor‐1 (IGF1) play an important role in mammalian development, cell proliferation and lifespan. Especially in cases of tumor growth there is an urgent need to control the GH/IGF1 axis. In this study we screened a 38,480-compound library, and in two consecutive rounds of analogues selection, we identified active lead compounds based on the following criteria: inhibition the GH receptor (GHR) activity and its downstream effectors Jak2 and STAT5, and inhibition of growth of breast and colon cancer cells. The most active small molecule (BM001) inhibited both the GH/IGF1 axis and cell proliferation with an IC50 of 10‐30 nM of human cancer cells. BM001 depleted GHR in human lymphoblasts. In preclinical xenografted experiments, BM001 showed a strong decrease in tumor volume in mice transplanted with MDA‐MB‐231 breast cancer cells. Mechanistically, the drug acts on the synthesis of the GHR. Our findings open the possibility to inhibit the GH/IGF1 axis with a small molecule.

2,737 views
11 citations
Open for submission
Frontiers Logo

Frontiers in Endocrinology

Endocrine Nutritional Metabolic Abnormalities and Tumors
Edited by Juan Kong, Yue Zhao, Chun-su Yuan, Zheng Huachuan
Deadline
25 November 2024
Submit a paper
Recommended Research Topics
Frontiers Logo

Frontiers in Endocrinology

Rare Endocrine and Neuroendocrine Tumors: Genetics and Molecular Aspects
Edited by Barbara Altieri, Antongiulio Faggiano, Enzo Lalli
62.4K
views
13
articles
Frontiers Logo

Frontiers in Endocrinology

Substance and Energy Metabolism Associated with Neuroendocrine Regulation in Tumor Cells
Edited by Ruiqin Han, Xiaochen Yuan, Qingbin Wu, Chenyu Sun, Peixin Dong
156.4K
views
258
authors
41
articles
Frontiers Logo

Frontiers in Endocrinology

Pathology and Genetics of Endocrine and Neuroendocrine Tumors
Edited by Huanwen Wu, Feng Ye, Zhiyan Liu, DELMAR MUNIZ LOURENCO Jr.
20K
views
50
authors
6
articles
Frontiers Logo

Frontiers in Endocrinology

New molecular pathways in thyroid cancer and pathophysiology: Role of coding and noncoding genes
Edited by Cesar Seigi Fuziwara, Murilo Vieira Geraldo, Juan Pablo Nicola
32.7K
views
89
authors
9
articles
Deadline
15 Jul 2024
Submit